{"created":"2022-02-02T02:06:58.914121+00:00","id":2012364,"links":{},"metadata":{"_buckets":{"deposit":"85b513bd-d6cf-479e-b3db-df501fc03757"},"_deposit":{"id":"2012364","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"2012364"},"status":"published"},"_oai":{"id":"oai:u-ryukyu.repo.nii.ac.jp:02012364","sets":["1642838163960:1642838338003","1642838403551:1642838407795"]},"author_link":[],"item_1617186331708":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_1551255647225":"Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial)","subitem_1551255648112":"en"}]},"item_1617186419668":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Hama, Taketsugu","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Nakanishi, Koichi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Ishikura, Kenji","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Ito, Shuichi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Nakamura, Hidefumi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Sako, Mayumi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Saito-Oba, Mari","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Nozu, Kandai","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Shima, Yuko","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Iijima, Kazumoto","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Yoshikawa, Norishige","creatorNameLang":"en"}]}]},"item_1617186476635":{"attribute_name":"Access Rights","attribute_value_mlt":[{"subitem_1522299639480":"open access","subitem_1600958577026":"http://purl.org/coar/access_right/c_abf2"}]},"item_1617186499011":{"attribute_name":"Rights","attribute_value_mlt":[{"subitem_1522650717957":"en","subitem_1522651041219":"Creative Commons Attribution 4.0 International License"}]},"item_1617186609386":{"attribute_name":"Subject","attribute_value_mlt":[{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"Mizoribine"},{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"Frequently-relapsing nephrotic syndrome"},{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"Steroid-sensitive nephrotic syndrome"}]},"item_1617186626617":{"attribute_name":"Description","attribute_value_mlt":[{"subitem_description":"Background: Eighty percent of children with steroid-sensitive nephrotic syndrome (SSNS) relapse within 2 years and 40-50% patients show frequently-relapsing nephrotic syndrome (FRNS). Patients showing a relapse within 6 months after initial remission are at high risk of FRNS. Since frequent prednisolone treatment for FRNS induces severe prednisolone side effects, development of a treatment to prevent patients from shifting to FRNS is desirable. Mizoribine is an immunosuppressive drug with fewer side effects than prednisolone. Recent studies reported the efficacy of high-dose mizoribine in children with FRNS. Methods/design: We conduct a multicenter, open, randomized controlled trial to investigate the efficacy and safety of standard prednisolone plus high-dose mizoribine therapy in children with SSNS showing a relapse within 6 months after an initial remission. Patients are allocated to either standard prednisolone alone treatment group, or standard prednisolone plus high-dose mizoribine group. For the former group, mizoribine is administered at a dose of 10 mg/kg/day once daily and continued for 2 years. The primary endpoint is the duration to frequent relapse. Discussion: The results provide important data on use of high-dose mizoribine to prevent SSNS patients from shifting to FRNS. Since blood concentrations of mizoribine have not been investigated in detail until now, there is a possibility that mizoribine is underestimated in favor of other immunosuppressive drugs. In future, high-dose mizoribine therapy may lead to prevention of relapse in children at high risk of FRNS, and to decreased total dose of prednisolone.","subitem_description_type":"Other"},{"subitem_description":"論文","subitem_description_type":"Other"}]},"item_1617186643794":{"attribute_name":"Publisher","attribute_value_mlt":[{"subitem_1522300295150":"en","subitem_1522300316516":"Springer Nature"}]},"item_1617186702042":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_1551255818386":"eng"}]},"item_1617186783814":{"attribute_name":"Identifier","attribute_value_mlt":[{"subitem_identifier_type":"HDL","subitem_identifier_uri":"http://hdl.handle.net/20.500.12000/45852"}]},"item_1617186920753":{"attribute_name":"Source Identifier","attribute_value_mlt":[{"subitem_1522646500366":"ISSN","subitem_1522646572813":"1471-2369"}]},"item_1617186941041":{"attribute_name":"Source Title","attribute_value_mlt":[{"subitem_1522650068558":"en","subitem_1522650091861":"BMC Nephrology"}]},"item_1617187056579":{"attribute_name":"Bibliographic Information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-09-10","bibliographicIssueDateType":"Issued"},"bibliographicVolumeNumber":"19"}]},"item_1617258105262":{"attribute_name":"Resource Type","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_1617265215918":{"attribute_name":"Version Type","attribute_value_mlt":[{"subitem_1522305645492":"VoR","subitem_1600292170262":"http://purl.org/coar/version/c_970fb48d4fbd8a85"}]},"item_1617353299429":{"attribute_name":"Relation","attribute_value_mlt":[{"subitem_1522306287251":{"subitem_1522306382014":"DOI","subitem_1522306436033":"https://doi.org/10.1186/s12882-018-1033-z"}},{"subitem_1522306287251":{"subitem_1522306382014":"DOI","subitem_1522306436033":"https://doi.org/10.1186/s12882-018-1033-z"}},{"subitem_1522306287251":{"subitem_1522306382014":"URI","subitem_1522306436033":"http://creativecommons.org/licenses/by/4.0/"}}]},"item_1617605131499":{"attribute_name":"File","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","filename":"s12882-018-1033-z.pdf","mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://u-ryukyu.repo.nii.ac.jp/record/2012364/files/s12882-018-1033-z.pdf"},"version_id":"1c334f56-03bd-464d-8f98-cd28181eca5f"}]},"item_title":"Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial)","item_type_id":"15","owner":"1","path":["1642838338003","1642838407795"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2020-05-21"},"publish_date":"2020-05-21","publish_status":"0","recid":"2012364","relation_version_is_last":true,"title":["Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial)"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-08-03T05:31:26.718801+00:00"}